Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry
Joint Authors
Firenzuoli, Fabio
Gensini, Gian Franco
Chinou, Ioanna
Cardia, Luigi
Calapai, Fabrizio
Sorbara, Emanuela Elisa
Firenzuoli, Bernardo
Ricca, Valdo
Mannucci, Carmen
Calapai, Gioacchino
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-08-29
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Background.
Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa.
CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders.
Objective.
The aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD in psychiatric patients.
Methods.
This review collects the main scientific findings on the potential role of CBD in the psychiatric field, and results of clinical trials carried out on psychiatric patients are commented.
A research was conducted in the PUBMED, SCOPUS, and ScienceDirect databases using combinations of the words cannabidiol, psychiatry, and neuropsychiatric.
Results.
Preclinical and clinical studies on potential role of CBD in psychiatry were collected and further discussed.
We found four clinical studies describing the effects of CBD in psychiatric patients: two studies about schizophrenic patients and the other two studies carried out on CBD effects in patients affected by generalized social anxiety disorder (SAD).
Conclusion.
Results from these studies are promising and suggest that CBD may have a role in the development of new therapeutic strategies in mental diseases, and they justify an in-depth commitment in this field.
However, clinical evidence we show for CBD in psychiatric patients is instead still poor and limited to schizophrenia and anxiety, and it needs to be implemented with further studies carried out on psychiatric patients.
American Psychological Association (APA)
Calapai, Gioacchino& Mannucci, Carmen& Chinou, Ioanna& Cardia, Luigi& Calapai, Fabrizio& Sorbara, Emanuela Elisa…[et al.]. 2019. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1148971
Modern Language Association (MLA)
Calapai, Gioacchino…[et al.]. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1148971
American Medical Association (AMA)
Calapai, Gioacchino& Mannucci, Carmen& Chinou, Ioanna& Cardia, Luigi& Calapai, Fabrizio& Sorbara, Emanuela Elisa…[et al.]. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1148971
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148971